# Oryza

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oryza

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.oryzapharma.com
- Latest round: Series C (Dec 29, 2025)
- Investors on record: 4

## About

Established in 2016 and based in Shenzhen, China, Shenzhen Ruihua Pharmaceutical Technology Co., Ltd., trading as Oryza, operates as a pharmaceutical company dedicated to researching and developing new and improved drugs and generic drugs. The company's research and development facility is in Coral Springs, Florida, USA, and it has sub-branch offices in Beijing and Hong Kong. In February 2023, Oryza cooperated with the American company Reflexiv+. In December 2025, Oryza raised a series C funding from new investor China Venture Capital.
The company mainly produces new drugs and generic drugs with sustained and controlled-release properties. There are five drug forms which are solid, liquid, semi-solid, patch, and nanospray. The products can be used in curing diabetes, digestive system diseases, cardiovascular and cerebrovascular diseases, malignant tumors, and other symptoms. Oryza’s release technology can be used in natural plants, herbal traditional Chinese medicine, biopharmaceutical ingredients, and other fields. The products are also exported to the US.
The company's revenue is generated by providing generic drugs and improved new drugs.

## Funding rounds

- Series C, Dec 29, 2025 — China Venture Capital
- Series B, Sep 7, 2021 — ASB Ventures, Goldport Capital
- Series A, Oct 15, 2019 — Cowin Capital

## Investors

- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series A
- ASB Ventures (https://capitalatlas.ai/funds/asb-ventures) — Series B
- Goldport Capital (https://capitalatlas.ai/funds/goldport-capital) — Series B
- China Venture Capital (https://capitalatlas.ai/funds/china-venture-capital) — Series C